Eureka Bio
PrivateLast Round
Series B
Extension
Feb 21, 2024
Total Funding Raised
$56.6M
Momentum Score
50 /100
Company Overview
Eureka Bio, legally known as Shenzhen Eureka Biotechnology Co., Limited, is a technology company that provides solutions for the cell and gene therapy (CGT) industry. The company develops and offers automated cell processing systems, such as the CellSep® PRO, and scalable viral vector manufacturing platforms like the EuLV™ Lentiviral Vector Production System. Its mission is to address key challenges in the CGT field, particularly in reducing costs and improving efficiency for large-scale production. Founded in 2014, the company has a global presence with its headquarters in Shenzhen, China, and offices in other Chinese cities, the United States, and Hong Kong. Eureka Bio is a venture-backed company, having raised significant funding, including a Series B+ round of over $40 million in March 2024, to support its commercialization and global expansion efforts.
Sector
Healthcare & Life Sciences
Verticals
Biotech Equipment, Biotechnology, Smart Manufacturing, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Eureka Bio Comps
Public and private peers based on sector, stage, and business model.
Eureka Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Feb 21, 2024 | ||||
| Series B | Jun 21, 2022 |
Eureka Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ABC Capital | Series B Extension |
| F-Prime Capital | Series B |
| Shenzhen Dachen Caizhi Venture Capital Management | Series B Extension |
| Clearwater Bay Capital | Series B Extension |
| Tasly Capital | Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 16, 2026
Monthly visitors grew 382% MoM, reaching 1.1K.
- Feb 18, 2025
Collaborates with VectorBuilder Inc. to lower viral vector production costs.
Eureka Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Eureka Bio's valuation, stock price, and market status.
